Regeneron Pharmaceuticals, Inc.
Regeneron Reports Q4 and Full Year 2025 Financial Results
Summary
Regeneron Pharmaceuticals, Inc. announced its financial and operating results for the quarter and full year ended December 31, 2025. Total revenues increased by 1% to $14.3 billion for the full year. Regeneron's blockbuster medicines, including Dupixent and EYLEA, drove revenue growth. Additionally, the company secured multiple label expansions and new approvals for its products. However, there was a decline in the GAAP net income for the quarter and full year. Regeneron also provided guidance for 2026, with a focus on prioritizing internal investments and enhancing shareholder returns.
Profitelligence Alerts
Get alerts for REGN
Be first to know when Regeneron Pharmaceuticals, Inc. files with the SEC.
Filing Categories
Advertisement
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of medicines for serious medical conditions. The company's primary function is to address unmet medical needs through innovative treatments derived from its robust pipeline of pharmaceutical products. Regeneron is particularly notable for its contributions to the healthcare industry with products that target ailments such as eye diseases, inflammatory conditions, and cancer. Among its key offerings are EYLEA, an injection for retinal diseases, and Dupixent, used to treat eczema and asthma. Based in Tarrytown, New York, Regeneron employs cutting-edge technologies like its VelociSuite platform, which enhances drug invention capabilities. The company plays a significant role in the biotechnology sector by delivering high-impact therapies that improve patient outcomes. With a strong emphasis on research and development, Regeneron continues to expand its impact across global markets, providing vital solutions to complex health challenges.
Official SEC Documents
Advertisement